As per the multi-year strategic research alliance, Evotec will apply its drug discovery platform to design novel treatments and is eligible to receive undisclosed research funding and milestones.
The multi-target collaboration aims to deliver small molecule preclinical development and investigational new drug (IND) ready candidates, according to Evotec.
Per Falk, chief science officer of Ferring, said in a press release: "To achieve leadership in reproductive medicine and women's health, we are expanding beyond our historical expertise in peptides and tackling molecular targets that are best addressed using small molecule therapeutics.”
Evotec has announced several partnerships this year, including those with Celgene, Almirall, Novo Nordisk, and Centogene, among others.
Additionally, earlier this month, Evotec signed its fourth translational research agreement with Sanofi as part of a five-year alliance.
The companies in March announced that Sanofi would license more than ten R&D assets to Evotec as part of an open platform alliance designed to advance anti-infective drug discovery and development. The deal included an upfront payment of approximately $74m to cover research and development, administrative, and facility-based costs.
